MRK: Strategic "Terns" acquisition and Keytruda Qlex launch provide defensive buffer against 2028 patent cliff

Merck & Co. (MRK) is currently operating at a pivotal crossroads, balancing the record-breaking success of its oncology franchise with the looming 2028 "patent cliff" for its star drug, Keytruda. As of March 26, 2026, the stock is trading at $118.93 USD on the NYSE, reflecting a slight daily decline of 0.37%. Despite this minor pullback, the company has delivered a solid 24.9% total return over the past 12 months, significantly outperforming many of its big-pharma peers as investors flock to its resilient cash flows and aggressive acquisition strategy.

The Infrastructure Vector: Diversifying Beyond the "Crown Jewel"

• Rating: V2 (Low-to-Moderate Volatility / High Stability)
• Logic: Merck’s investment thesis is centered on its ability to replace the $31.7 billion in annual revenue generated by Keytruda. The logic is a "bridge" strategy: using the current massive cash flows to acquire late-stage biotech assets. The recent $6.7 billion acquisition of Terns Pharmaceuticals on March 25, 2026, is a prime example, adding a promising chronic myeloid leukemia (CML) candidate, TERN-701, to challenge Novartis's dominance in the hematology space.

Key Ideas: Organizational Splits and Pipeline Milestones

• The February 2026 Split: CEO Robert Davis recently divided the Human Health division into two distinct units: "Oncology" and "Specialty, Pharma & Infectious Diseases." This move is designed to ensure that non-cancer assets, like the cardiovascular blockbuster-to-be Winrevair, receive the same commercial focus as Keytruda.
• Keytruda Qlex (Subcutaneous): A major 2026 catalyst is the rollout of the subcutaneous formulation of Keytruda. By moving patients from 30-minute IV infusions to a rapid injection, Merck aims to retain market share and extend the life of the franchise even after the primary patent expires.
• IRA Headwinds: The Inflation Reduction Act (IRA) is a tangible risk; Merck's diabetes drug Januvia already saw a 79% Medicare price cut in 2026, serving as a warning for future price negotiations on high-volume biologics.
• Animal Health "Hidden Gem": Accounting for 11% of revenue, Merck's Animal Health division remains a critical stabilizer because it is largely "private pay" and insulated from government drug-pricing pressures.

The Growth Engine: The "Sovereign Health" Narrative

The primary engine for Merck's valuation is the successful launch of Winrevair for pulmonary arterial hypertension (PAH) and the development of MK-0616, an oral PCSK9 inhibitor for high cholesterol. The "real story" is Merck's transition into a more diverse "specialty-lite" powerhouse. By investing heavily in oral formulations of drugs that were previously only available via injection, Merck is making chronic disease management easier for patients while protecting its margins. This innovation pipeline, fueled by over $30 billion in recent M&A (including Verona Pharma and Cidara), aims to unlock $70 billion in new annual opportunities by the mid-2030s.

Bullish Indicators & Risk Factors: The 2026 Pipeline Balance

Fair Value Analysis: Valuation Amidst the "Patent Cliff" Concerns

Using your fair value method, which factors in a 16x Exit P/E multiple on 2027 adjusted earnings and accounts for the $2.5 billion in expected 2026 policy headwinds, the valuation for MRK in USD is:

Opinion Section: Strategic Outlook and Performance Projections

Over the next 1 to 3 months, I expect Merck to trade within a range of $115 to $125. The market is currently digesting the Terns Pharmaceuticals deal, which will result in a one-time charge of $2.35 per share in the second quarter. While this impacts GAAP earnings, the underlying "core" oncology growth remains robust. Investors should watch for the Phase 3 readout of enlicitide (oral PCSK9) later this year; a positive result there would likely trigger a re-rating of the stock toward the $130 level.

Looking at the 1-year horizon, the narrative will center on the "Oncology Split" effectiveness. If the new standalone oncology unit can maintain Keytruda's 7% growth while the specialty unit accelerates Winrevair's rollout, Merck could easily hit its intrinsic fair value of $128.04. The dividend remains incredibly safe, supported by strong free cash flow, making this a "buy-and-hold" favorite for those seeking a mix of yield and defensive growth.

In the long-term (5+ years), Merck is essentially a bet on R&D execution. The company is effectively trying to "out-innovate" its own success. By 2028, we will know if the $70 billion in potential pipeline opportunities was a realistic projection or an optimistic corporate target. However, given their track record with Gardasil and Keytruda, Merck has proven it can dominate high-barrier-to-entry markets. As long as they continue to use their massive cash pile to snap up "best-in-class" candidates like TERN-701, they remain the premier defensive play in the pharmaceutical sector.

Summary of Outlook: The Defensive Pharma Leader

I arrived at the fair value of $128.04 USD by applying a 16x multiple to the projected 2027 earnings, which accounts for the company's 38% operating margins while baking in a "Keytruda discount" for the upcoming patent expiration. This fair value calculation affects the stock by suggesting it is currently 9% undervalued relative to its near-term earnings potential and pipeline optionality. In summary, Merck is a high-cash-flow machine that is successfully buying its way into a post-Keytruda future, offering investors a rare combination of stability and a massive $70 billion growth horizon.